Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8IY92
UPID:
SLX4_HUMAN
Alternative names:
BTB/POZ domain-containing protein 12
Alternative UPACC:
Q8IY92; Q69YT8; Q8TF15; Q96JP1
Background:
Structure-specific endonuclease subunit SLX4, also known as BTB/POZ domain-containing protein 12, plays a pivotal role in maintaining genome stability. It enhances the activity of various endonucleases, resolving harmful DNA structures from replication, recombination intermediates, and DNA damage. SLX4 is crucial in resolving DNA secondary structures, cleaving branched DNA substrates, and interacting with multiple endonucleases to promote the cleavage of complex DNA structures.
Therapeutic significance:
SLX4's involvement in Fanconi anemia complementation group P, a disorder impacting bone marrow and predisposing individuals to malignancies, underscores its therapeutic potential. Understanding SLX4's role could open doors to novel therapeutic strategies for treating Fanconi anemia and related genomic instability disorders.